kinase inhibitors
kinase inhibitors

Kinase inhibitors

Confidence and certainty with USP standards and solutions

Previous Next

Kinase Inhibitors

Innovative treatments

By targeting specific enzymes central to managing how cells work—including cell signaling, growth, and division—kinase inhibitors have reshaped the paradigm for how many diseases are tackled today.

Providing targeted approaches for attacking advanced-stage cancers, reducing rejection rates of organ transplantations, and delivering precision treatments based on specific genetic mutations, kinase inhibitors such as erlotinib, gefitinib, nilotinib, regorafenib, sorafenib, sunitinib, everolimus, and sirolimus have vastly improved quality of life for many patients.

But only generic versions of these drugs can help ensure patients worldwide reap the benefits of these innovative treatments.

Confidence and certainty with USP standards and solutions

Well-accepted by regulators worldwide, validated methods published in USP-NF monographs and general chapters and official USP Reference Standards play a critical role in accelerating drug development and minimizing risks for manufacturers seeking to release and gain approval for drug products.

Use USP kinase inhibitor Reference Standards, methods and other solutions and operate with a high level of certainty and confidence in your analytical results in drug development and manufacturing.

Click below for our portfolio of USP kinase inhibitor solutions:

Please note: some links below require a USP-NF account to access.

Erlotinib Hydrochloride - COMING SOON

Erlotinib Tablets - COMING SOON

Included General Chapters:

Included Excipients:

Erlotinib

Erlotinib

Please note: some links below require a USP-NF account to access.

Erlotinib Hydrochloride - COMING SOON

Erlotinib Tablets - COMING SOON

Included General Chapters:

Included Excipients:

Please note: some links below require a USP-NF account to access.

Everolimus 

Included General Chapters:

Everolimus

Everolimus

Please note: some links below require a USP-NF account to access.

Everolimus 

Included General Chapters:

Please note: some links below require a USP-NF account to access.

Gefitinib

Gefitinib Tablets

Included General Chapters:

Included Excipients:

Gefitinib

Gefitinib

Please note: some links below require a USP-NF account to access.

Gefitinib

Gefitinib Tablets

Included General Chapters:

Included Excipients:

Please note: some links below require a USP-NF account to access.

Nilotinib 

Included General Chapters:

Included Excipients:

Nilotinib

Nilotinib

Please note: some links below require a USP-NF account to access.

Nilotinib 

Included General Chapters:

Included Excipients:

Please note: some links below require a USP-NF account to access.

Regorafenib

Included General Chapters

Excipients included with this molecule

Regorafenib

Regorafenib

Please note: some links below require a USP-NF account to access.

Regorafenib

Included General Chapters

Excipients included with this molecule

Please note: some links below require a USP-NF account to access.

Sirolimus - COMING SOON

Sirolimus Tablets - COMING SOON

Included General Chapters:

Excipients included with this molecule

Sirolimus

Sirolimus

Please note: some links below require a USP-NF account to access.

Sirolimus - COMING SOON

Sirolimus Tablets - COMING SOON

Included General Chapters:

Excipients included with this molecule

Please note: some links below require a USP-NF account to access.

Sorafenib Tosylate

Sorafenib Tablets

Included General Chapters

Excipients included with this molecule:

Pharmaceutical Analytical Impurities:

Sorafenib

Sorafenib

Please note: some links below require a USP-NF account to access.

Sorafenib Tosylate

Sorafenib Tablets

Included General Chapters

Excipients included with this molecule:

Pharmaceutical Analytical Impurities:

Sunitinib Malate - COMING SOON

Included General Chapters:

Included Excipients:

Pharmaceutical Analytical Impurities

Sunitinib

Sunitinib

Sunitinib Malate - COMING SOON

Included General Chapters:

Included Excipients:

Pharmaceutical Analytical Impurities

*Pharmaceutical Analytical Impurities are released using a process developed by USP’s subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP’s Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.